Ownership history in Frazier Life Sciences Management, L.P. · 16 quarters on record
This page tracks every 13F SEC filing in which Frazier Life Sciences Management, L.P. reported a position in KALVISTA PHARMACEUTICALS INC (KALV). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | UNCHANGED | 5,039,867 | — | 0% | 2.19% | $81.4M | $16.15 |
| 2025 Q3 | ADDED | 5,039,867 | +152,000 | +3.1% | 1.84% | $61.4M | $12.18 |
| 2025 Q2 | UNCHANGED | 4,887,867 | — | 0% | 2.21% | $55.3M | $11.31 |
| 2025 Q1 | UNCHANGED | 4,887,867 | — | 0% | 2.58% | $56.4M | $11.54 |
| 2024 Q4 | ADDED | 4,887,867 | +1,200,000 | +32.5% | 1.72% | $41.4M | $8.47 |
| 2024 Q3 | UNCHANGED | 3,687,867 | — | 0% | 1.71% | $42.7M | $11.58 |
| 2024 Q2 | UNCHANGED | 3,687,867 | — | 0% | 2.03% | $43.4M | $11.78 |
| 2024 Q1 | ADDED | 3,687,867 | +65,573 | +1.8% | 1.85% | $43.7M | $11.86 |
| 2023 Q4 | ADDED | 3,622,294 | +383,435 | +11.8% | 2.37% | $44.4M | $12.25 |
| 2023 Q3 | UNCHANGED | 3,238,859 | — | 0% | 2.07% | $31.2M | $9.63 |
As of 2025 Q4 — sorted by position size